



Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

### AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:



$R^1$  is halogen, CN,  $\text{NO}_2$ , or  $\text{V}_m\text{R}$ ;  
 $Z^1$  and  $Z^3$  are each independently  $\text{CR}_2^Z$ ;  
 $Z^2$  is  $\text{CR}^1$ ;  
each occurrence of  $R^2$  is independently halogen, CN,  $\text{NO}_2$ , or  $\text{U}_n\text{R}'$ ;  
 $R^2$  is  $\text{U}_n\text{R}'$ ;  
each occurrence of  $R^4$  is independently halogen, CN,  $\text{NO}_2$ , or  $\text{V}_m\text{R}$ ;  
each occurrence of U or V is independently an optionally substituted  $\text{C}_{1-6}$  alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by  $-\text{NR}-$ ,  $-\text{S}-$ ,  $-\text{O}-$ ,  $-\text{CS}-$ ,  $[[-\text{CO}_2-]]$ ,  $-\text{OCO}-$ ,  $[[-\text{CO}-]]$ ,  $-\text{COCO}-$ ,  $-\text{CONR}-$ ,  $-\text{NRCO}-$ ,  $-\text{NRCO}_2-$ ,  $-\text{SO}_2\text{NR}-$ ,  $-\text{NRSO}_2-$ ,  $-\text{CONRNR}-$ ,  $-\text{NRCONR}-$ ,  $-\text{OCONR}-$ ,  $-\text{NRNR}-$ ,  $-\text{NRSO}_2\text{NR}-$ ,  $-\text{SO}-$ , or  $-\text{SO}_2-$ ;

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862


m and n are each independently 0 or 1;

each occurrence of R is independently hydrogen or an optionally substituted C<sub>1-6</sub> aliphatic group; and each occurrence of R' is independently hydrogen or an optionally substituted C<sub>1-6</sub> aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R and R', two occurrences of R, or two occurrences of R', are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

Q<sup>1</sup> is -CO-;

R<sup>3</sup> is Q<sup>2</sup>-Ar<sup>1</sup>, wherein Q<sup>2</sup> is -(CHR<sup>6</sup>)<sub>q</sub>-, where q is 1, 2, or 3,

or R<sup>2</sup> and Q<sup>1</sup>-R<sup>3</sup>, taken together with the intervening nitrogen atom, form the cyclic



group: , where s is 1 or 2, each occurrence of Y is independently, as valency and stability permit, -CO-, -CS-, -SO<sub>2</sub>-, -O-, -S-, -NR<sup>5</sup>-, or -C(R<sup>5</sup>)<sub>2</sub>-, and R<sup>5</sup> is U<sub>n</sub>R';

Q<sup>3</sup> is a bond or a C<sub>1-6</sub> alkylidene chain, wherein up to two methylene units of the chain are each optionally and independently replaced by -S-, -O-, -CS-, -CO<sub>2</sub>-, -OCO-, -CO-, -COCO-, -CONR'-, -NR'CO-, -NR'CO<sub>2</sub>-, -SO<sub>2</sub>NR'-, -NR'SO<sub>2</sub>-, -CONR'NR'-, -NR'CONR'-, -OCONR'-, -NR'NR'-, -NR'SO<sub>2</sub>NR'-, -SO-, or -SO<sub>2</sub>-; and wherein any carbon atom in the one or more methylene units is optionally substituted with one or two occurrences of R<sup>6</sup>, wherein each occurrence of R<sup>6</sup> is independently halogen, CN, NO<sub>2</sub>, or U<sub>n</sub>R', or two occurrences of R<sup>6</sup>, or R' and R<sup>6</sup>, taken together with the atoms to which

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

they are bound, form an optionally substituted 3-6-membered cycloalkyl, heterocyclyl, aryl or heteroaryl ring; and

Ar<sup>1</sup> is a 5-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from oxygen or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from oxygen or sulfur; wherein Ar<sup>1</sup> is optionally substituted with 0-5 independent occurrences of TR<sup>7</sup>; wherein T is a bond or is a C<sub>1</sub>-C<sub>6</sub> alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -NR-, -S-, -O-, -CS-, -CO<sub>2</sub>-, -OCO-, -CO-, -COCO-, -CONR-, -NRCO-, -NRCO<sub>2</sub>-, -SO<sub>2</sub>NR-, -NRSO<sub>2</sub>-, -CONRNR-, -NRCONR-, -OCONR-, -NRNR-, -NRSO<sub>2</sub>NR-, -SO-, or -SO<sub>2</sub>;

Ar<sup>2</sup> is a 5-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar<sup>2</sup> is optionally substituted with 0-5 independent occurrences of TR<sup>7</sup>; wherein T is a bond or is a C<sub>1</sub>-C<sub>6</sub> alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -NR-, -S-, -O-, -CS-, -CO<sub>2</sub>-, -OCO-, -CO-, -COCO-, -CONR-, -NRCO-, -NRCO<sub>2</sub>-, -SO<sub>2</sub>NR-, -NRSO<sub>2</sub>-, -CONRNR-, -NRCONR-, -OCONR-, -NRNR-, -NRSO<sub>2</sub>NR-, -SO-, or -SO<sub>2</sub>; [[and]]

each occurrence of R<sup>7</sup> is independently R', halogen, NO<sub>2</sub>, or CN;


each of the optional substituents of said aryl or heteroaryl ring is selected from halogen; -R°; -OR°; -SR°; phenyl optionally substituted with R°; -O(phenyl), optionally substituted with R°; -(CH<sub>2</sub>)<sub>1-2</sub>(phenyl), optionally substituted with R°; -CH=CH(phenyl), optionally substituted with R°; -NO<sub>2</sub>; -CN; -N(R°)<sub>2</sub>; -NR°C(O)R°; -NR°C(S)R°; -NR°C(O)N(R°)<sub>2</sub>; -NR°C(S)N(R°)<sub>2</sub>; -NR°CO<sub>2</sub>R°; -NR°NR°C(O)R°;

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

-NR°NR°C(O)N(R°)<sub>2</sub>; -NR°NR°CO<sub>2</sub>R°; -C(O)C(O)R°; -C(O)CH<sub>2</sub>C(O)R°; -CO<sub>2</sub>R°; -C(O)R°; -C(S)R°; -C(O)N(R°)<sub>2</sub>; -C(S)N(R°)<sub>2</sub>; -OC(O)N(R°)<sub>2</sub>; -OC(O)R°; -C(O)N(OR°)R°; -C(NOR°)R°; -S(O)<sub>2</sub>R°; -S(O)<sub>3</sub>R°; -SO<sub>2</sub>N(R°)<sub>2</sub>; -S(O)R°; -NR°SO<sub>2</sub>N(R°)<sub>2</sub>; -NR°SO<sub>2</sub>R°; -N(OR°)R°; -C(=NH)-N(R°)<sub>2</sub>; -P(O)<sub>2</sub>R°; -PO(R°)<sub>2</sub>; -OPO(R°)<sub>2</sub>; -(CH<sub>2</sub>)<sub>0-2</sub>NHC(O)R°; wherein each independent occurrence of R° is selected from hydrogen, an optionally substituted C<sub>1-6</sub> aliphatic, an unsubstituted 5-6 membered heteroaryl or heterocyclic ring, phenyl, -O(phenyl), or -CH<sub>2</sub>(phenyl), wherein optional substituents on the aliphatic group of R° are selected from NH<sub>2</sub>, NH(C<sub>1-4</sub>aliphatic), N(C<sub>1-4</sub>aliphatic)<sub>2</sub>, halogen, C<sub>1-4</sub>aliphatic, OH, O(C<sub>1-4</sub>aliphatic), NO<sub>2</sub>, CN, CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-4</sub>aliphatic), O(haloC<sub>1-4</sub>aliphatic), or haloC<sub>1-4</sub>aliphatic, or two independent occurrences of R°, on the same substituent or different substituents, taken together with the atom(s) to which each R° group is bound, form a 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and

each of the optional substituents on said alkylidene chain, aliphatic, cycloalkyl, or heterocyclyl is selected from the list of optional substituents of optional substituents for aryl and heteroaryl rings and further comprise =O, =S, =NNHR°, =NN(R°)<sub>2</sub>, =NNHC(O)R°, =NNHCO<sub>2</sub>(alkyl), =NNHSO<sub>2</sub>(alkyl), or =NR°, where each R° is independently selected from hydrogen or a C<sub>1-6</sub> aliphatic group;

provided that:



for compounds having the structure:

R<sup>3</sup> is not any one of the following groups: -CH<sub>2</sub>(3-NHCOPh-phenyl), -CH<sub>2</sub>-pyrrolidine, unsubstituted benzyl, -CH<sub>2</sub>-naphthyl, -CH<sub>2</sub>CH<sub>2</sub>-3-(4-Cl-phenyl)-1-phenyl-1-H-pyrazol-4-yl, or -CH<sub>2</sub>(1,3-dioxoisindole).

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

2-3. (Canceled)

4. (Previously presented) The compound of claim 1, wherein  $R^2$  is hydrogen, or is  $U_nR'$ , where  $n$  is 1, and  $U$  is a  $C_{1-6}$  alkylidene chain wherein one or two methylene units are optionally and independently replaced by O, NR, S, or C(O).


5. (Previously presented) The compound of claim 1, wherein  $U$  is  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-CH_2O-$ ,  $-CH_2S-$ ,  $-CH_2NR-$ ,  $-CH_2CH_2O-$ ,  $-CH_2CH_2S-$ ,  $-CH_2CH_2NR-$ ,  $-CH_2CH_2CH_2O-$ ,  $-CH_2CH_2CH_2S-$ ,  $-CH_2CH_2CH_2NR-$ ,  $-CH_2CH_2CH_2CH_2O-$ ,  $-CH_2CH_2CH_2CH_2S-$ ,  $-CH_2CH_2CH_2CH_2NR-$ ,  $-CH_2CH_2OCH_2CH_2-$ ,  $-(CH_2)_4NHCH_2-$ ,  $-(CH_2)_3NHCH_2CH_2-$ , or  $-CH_2CH_2NHCH_2CH_2-$ , and preferred  $R'$  groups are hydrogen,  $C_1$ - $C_4$ alkyl, optionally substituted tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridinyl, phenyl, or cyclohexyl, or  $R$  and  $R'$ , taken together with the nitrogen atom to which they are bound, form an optionally substituted 5- or 6-membered heterocyclyl ring.

6-7. (Canceled)

8. (Previously presented) The compound of claim 1, wherein  $R^6$  is  $CH_2OH$ ,  $CH_2CH_2OH$ ,  $OH$ ,  $OMe$ ,  $OEt$ ,  $NH_2$ ,  $NH(Me)$ ,  $NH(Et)$ ,  $N(Me)(Me)$ ,  $CH_2NH_2$ ,  $CH_2CH_2NH_2$ ,  $NHCO_2t$ -butyl, phenyl, cyclopentyl, methyl, ethyl, isopropyl, cyclopropyl,  $NH(CH_2)_3NH_2$ ,  $NH(CH_2)_2NH_2$ ,  $NH(CH_2)_2NH(Et)$ ,  $NHCH_2$ pyridyl,  $NHSO_2$ phenyl,  $NHC(O)CH_2C(O)Ot$ -butyl,  $NHC(O)CH_2NH_3$ , and  $NHCH_2$ -imidazol-4-yl.

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

9. (Previously presented) The compound of claim 3, wherein  $\text{Ar}^1$  is:



wherein  $t$  is 0, 1, 2, 3, 4 or 5, and wherein any  $\text{Ar}^1$  is bonded to  $\text{Q}^2$  through any substitutable carbon atom, and wherein one or more hydrogen atoms on any substitutable carbon atom is substituted with one or more independent occurrences of  $\text{TR}^7$ .

10. (Previously presented) The compound of claim 9, wherein  $\text{Ar}^1$  is **a**, **e**, **i**, **k**, **cc**, **jj**, or **pp**.

11. (Original) The compound of claim 9, wherein  $\text{T}$  is a bond or is an optionally substituted  $\text{C}_{1-6}$  alkylidene chain wherein one or two methylene units are optionally and

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

independently replaced by -O-, -NR-, -S-, -SO<sub>2</sub>-, -COO-, -CO-, -OSO<sub>2</sub>-, -NRSO<sub>2</sub>-, -CONR-, or -SO<sub>2</sub>NR-, and R<sup>7</sup> is R' or halogen.

12. (Original) The compound of claim 9, wherein each occurrence of TR<sup>7</sup> is independently -C<sub>1-3</sub>alkyl, -OR', -SR', -CF<sub>3</sub>, -OCF<sub>3</sub>, -SCF<sub>3</sub>, -F, -Cl, I, -Br, -COOR', -COR', -O(CH<sub>2</sub>)<sub>4</sub>N(R)(R'), -O(CH<sub>2</sub>)<sub>3</sub>N(R)(R'), -O(CH<sub>2</sub>)<sub>2</sub>N(R)(R'), -O(CH<sub>2</sub>)N(R)(R'), -O(CH<sub>2</sub>)<sub>4</sub>CON(R)(R'), -O(CH<sub>2</sub>)<sub>3</sub>CON(R)(R'), -O(CH<sub>2</sub>)<sub>2</sub>CON(R)(R'), -O(CH<sub>2</sub>)CON(R)(R'), -C(O)N(R)(R'), -(CH<sub>2</sub>)<sub>4</sub>OR', -(CH<sub>2</sub>)<sub>3</sub>OR', -(CH<sub>2</sub>)<sub>2</sub>OR', -CH<sub>2</sub>OR', optionally substituted phenyl or benzyl, -N(R)(R'), -(CH<sub>2</sub>)<sub>4</sub>N(R)(R'), -(CH<sub>2</sub>)<sub>3</sub>N(R)(R'), -(CH<sub>2</sub>)<sub>2</sub>N(R)(R'), -(CH<sub>2</sub>)N(R)(R'), or SO<sub>2</sub>N(R)(R'), NRSO<sub>2</sub>R', CON(R)(R'), or -OSO<sub>2</sub>R'.


13. (Canceled)

14. (Previously presented) The compound of claim 1, wherein Q<sup>3</sup> is a direct bond, or is -(CHR<sup>6</sup>)<sub>q</sub>-, -(CHR<sup>6</sup>)<sub>q</sub>O-, -(CHR<sup>6</sup>)<sub>q</sub>S-, -(CHR<sup>6</sup>)<sub>q</sub>S(O)<sub>2</sub>-, -(CHR<sup>6</sup>)<sub>q</sub>S(O)-, -(CHR<sup>6</sup>)<sub>q</sub>NR-, or -(CHR<sup>6</sup>)<sub>q</sub>C(O)-, wherein q is 0, 1, 2, or 3, and R<sup>6</sup> is R', -N(R)(R'), -(CH<sub>2</sub>)<sub>1-4</sub>N(R)(R'), -OR', -(CH<sub>2</sub>)<sub>1-4</sub>OR', -NR(CH<sub>2</sub>)<sub>1-4</sub>N(R)(R'), -NR(CH<sub>2</sub>)<sub>1-4</sub>SO<sub>2</sub>R', -NR(CH<sub>2</sub>)<sub>1-4</sub>COOR', or -NR(CH<sub>2</sub>)<sub>1-4</sub>COR', or two occurrences of R<sup>6</sup>, taken together with the atoms to which they are bound, form an optionally substituted 3-6-membered saturated, partially unsaturated, or fully unsaturated ring.

15. (Original) The compound of claim 14, wherein R<sup>6</sup> is CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>OH, OH, OMe, OEt, NH<sub>2</sub>, NH(Me), NH(Et), N(Me)(Me), CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, NHCO<sub>2</sub>t-butyl, phenyl, cyclopentyl, methyl, ethyl, isopropyl, cyclopropyl, NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NH(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, NH(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, NH(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, NHCH<sub>2</sub>pyridyl, NHSO<sub>2</sub>phenyl, NHC(O)CH<sub>2</sub>C(O)Ot-butyl, NHC(O)CH<sub>2</sub>NH<sub>3</sub>, and NHCH<sub>2</sub>-imidazol-4-yl.

Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862

16. (Previously presented) The compound of claim 1, wherein  $Ar^2$  is:




**a**




**b**




**c**




**d**




**e**




**f**




**g**



**h**



**i**



**j**



**k**



**l**



**m**



**n**



**o**



**p**



**q**




**r**



**s**



Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862



**t**



**u**



**v**



**w**



**x**



**y**




**z**




**aa**



**bb**



**cc**




**dd**




**ee**



**ff**




**gg**




**hh**




**ii**



**jj**




**kk**



**ll**

Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862



wherein  $t$  is 0, 1, 2, 3, 4 or 5, and wherein any  $Ar^2$  is bonded to  $Q^3$  through any substitutable nitrogen or carbon atom, and wherein one or more hydrogen atoms on any substitutable nitrogen or carbon atom is substituted with one or more independent occurrences of  $TR^7$ .

17. (Original) The compound of claim 16, wherein  $Ar^2$  is **a, b, e, g, h, i, j, k, n, r, cc, dd, ff, jj, ll, or pp**.

18. (Original) The compound of claim 16, wherein  $T$  is a bond or is an optionally substituted  $C_{1-6}$  alkylidene chain wherein one or two methylene units are optionally and independently replaced by  $-O-$ ,  $-NR-$ ,  $-S-$ ,  $-SO_2-$ ,  $-COO-$ ,  $-CO-$ ,  $-OSO_2-$ ,  $-NRSO_2-$ ,  $-CONR-$ , or  $-SO_2NR-$ , and  $R^7$  is  $R'$  or halogen.

19. (Original) The compound of claim 16, wherein each occurrence of  $TR^7$  is independently  $-C_{1-3}alkyl$ ,  $-OR'$ ,  $-SR'$ ,  $-CF_3$ ,  $-OCF_3$ ,  $-SCF_3$ ,  $-F$ ,  $-Cl$ ,  $I$ ,  $-Br$ ,  $-COOR'$ ,  $-COR'$ ,  $-O(CH_2)_4N(R)(R')$ ,  $-O(CH_2)_3N(R)(R')$ ,  $-O(CH_2)_2N(R)(R')$ ,  $-O(CH_2)N(R)(R')$ ,  $-O(CH_2)_4CON(R)(R')$ ,  $-O(CH_2)_3CON(R)(R')$ ,  $-O(CH_2)_2CON(R)(R')$ ,  $-O(CH_2)CON(R)(R')$ ,  $-C(O)N(R)(R')$ ,  $-(CH_2)_4OR'$ ,  $-(CH_2)_3OR'$ ,  $-(CH_2)_2OR'$ ,  $-CH_2OR'$ , optionally substituted phenyl or benzyl,  $-N(R)(R')$ ,  $-(CH_2)_4N(R)(R')$ ,  $-(CH_2)_3N(R)(R')$ ,  $-(CH_2)_2N(R)(R')$ ,  $-(CH_2)N(R)(R')$ , or  $SO_2N(R)(R')$ ,  $NRSO_2R'$ ,  $CON(R)(R')$ , or  $-OSO_2R'$ .

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

20. (Previously presented) The compound of claim 1, wherein  $R^5$  is hydrogen,  $(CH_2)_3OR'$ ,  $(CH_2)_2OR'$ ,  $(CH_2)OR'$ ,  $(CH_2)_3N(R')_2$ ,  $(CH_2)_2N(R')_2$ ,  $(CH_2)N(R')_2$ , or  $C_{1-4}$ aliphatic.

21-22. (Canceled)

23. (Original) The compound of claim 1, wherein each occurrence of  $R^1$  is independently hydrogen, halogen, optionally substituted  $C_{1-4}$ aliphatic, OR, SR, or  $N(R)_2$ .

24. (Previously presented) The compound of claim 23, wherein each occurrence of  $R^1$  is independently hydrogen, halogen,  $-CH_3$ ,  $-CH_2CH_3$ ,  $-OH$ ,  $-OCH_3$ ,  $-SCH_3$ ,  $-NH_2$ ,  $-N(CH_3)_2$ ,  $-N(CH_2CH_3)_2$ ,  $-NH(CH_2)_2NHCH_3$ ,  $-NH(cyclopropyl)$ ,  $-NH(CH_2)cyclopropyl$ , or  $-NH(CH_2)_2N(CH_3)_2$ .


25. (Original) The compound of claim 1, wherein each occurrence of  $R^Z$  is independently hydrogen, halogen,  $C_{1-4}$ aliphatic, OH, OR', or  $N(R)(R')$ .

26. (Original) The compound of claim 25, wherein each occurrence of  $R^Z$  is independently hydrogen, halogen, Me, OH, OMe,  $NH_2$ , or  $N(Me)_2$ .

27. (Currently amended) The compound of claim 1, wherein  $R^4$  groups are each independently hydrogen,  $C_{1-6}$ aliphatic, CN, ~~OR~~,  ~~$C(=O)OR$~~ ,  $C(=O)N(R)_2$ , or halogen.


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

28. (Previously presented) The compound of claim 1, wherein one occurrence of  $R^4$  is CN and compounds have the general structure **II-a**:



**II-a.**


29. (Previously presented) The compound of claim 1, wherein  $R^4$  is hydrogen and compounds have the general structure **III-a**:



**III-a.**

30. (Canceled)

31. (Previously presented) The compound of claim 1, wherein  $R^4$  is hydrogen and compounds have the general structure **VII-a**:




**VII-a.**

32. (Canceled)


Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862

33. (Previously presented) The compound of claim 1, wherein  $R^4$  is hydrogen and compounds have the general structure **XI-a**:




**XI-a.**


34. (Previously presented) The compound of claim 9, wherein  $Q^1$  is  $-CO-$ ,  $Q^2$  is  $CHR^6$ ,  $q$  is 1, 2, or 3, and compounds have one of formulas **XIV**, **XV**, or **XVI**:



**XIV**




**XV**




**XVI.**

35. (Previously presented) The compound of claim 9, wherein  $Q^1$  is  $-CO-$ ,  $Q^2$  is  $CHR^6$ ,  $q$  is 1, 2 or 3, and compounds have one of formulas **XVII**, **XVIII**, or **XIX**:


Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862



**XVII**



**XVIII**



**XIX.**

36. (Previously presented) The compound of claims 34 or 35, wherein compound variables are selected from one or more of the following groups:

- a) each occurrence of  $R^1$  is independently hydrogen, halogen, optionally substituted  $C_1$ - $C_4$ aliphatic, OR, SR, or  $N(R)_2$ ;
- b) each occurrence of  $R^1$  is independently hydrogen, halogen,  $-CH_3$ ,  $-CH_2CH_3$ ,  $-OH$ ,  $-OCH_3$ ,  $-SCH_3$ ,  $-NH_2$ ,  $-N(CH_3)_2$ ,  $-N(CH_2CH_3)_2$ ,  $-NH(CH_2)_2NHCH_3$ ,  $-NH(cyclopropyl)$ ,  $-NH(CH_2)cyclopropyl$ , or  $-NH(CH_2)_2N(CH_3)_2$ ;
- c) each occurrence of  $R^Z$  is independently hydrogen, halogen, optionally substituted  $C_1$ - $C_4$ aliphatic, OH,  $O(R')$ , or  $N(R)(R')$ ;
- d) each occurrence of  $R^Z$  is independently hydrogen, halogen, Me, OH, OMe,  $NH_2$ , or  $N(Me)_2$ ;
- e)  $R^2$  is hydrogen, or is  $U_nR'$ , where n is 1, and U is  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-CH_2O-$ ,  $-CH_2S-$ ,  $-CH_2NR-$ ,  $-CH_2CH_2O-$ ,  $-CH_2CH_2S-$ ,  $-CH_2CH_2NR-$ ,  $-CH_2CH_2CH_2O-$ ,  $-CH_2CH_2CH_2S-$ ,  $-CH_2CH_2CH_2NR-$ ,  $-CH_2CH_2CH_2CH_2O-$ ,  $-CH_2CH_2CH_2CH_2S-$ ,  $-CH_2CH_2CH_2CH_2NR-$ ,  $-CH_2CH_2OCH_2CH_2-$ ,  $-(CH_2)_4NHCH_2-$ ,  $-(CH_2)_3NHCH_2CH_2-$ , or

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

-CH<sub>2</sub>CH<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>-, and R' groups are hydrogen, C<sub>1</sub>-C<sub>4</sub>alkyl, optionally substituted tetrahydropyranyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridinyl, phenyl, or cyclohexyl, or R and R', taken together with the nitrogen atom to which they are bound, form an optionally substituted 5- or 6-membered heterocyclyl ring;

f) each occurrence of R<sup>4</sup> is independently hydrogen, C<sub>1-6</sub>aliphatic, CN, COR, COOR, CON(R)<sub>2</sub>, or halogen;

g) q is 1, 2, or 3;

h) R<sup>6</sup> is R', -N(R)(R'), -(CH<sub>2</sub>)<sub>1-4</sub>N(R)(R'), -OR', -(CH<sub>2</sub>)<sub>1-4</sub>OR', -NR(CH<sub>2</sub>)<sub>1-4</sub>N(R)(R'), -NR(CH<sub>2</sub>)<sub>1-4</sub>SO<sub>2</sub>R', -NR(CH<sub>2</sub>)<sub>1-4</sub>COOR', or -NR(CH<sub>2</sub>)<sub>1-4</sub>COR', or two occurrences of R<sup>6</sup>, taken together with the atoms to which they are bound, form an optionally substituted 3-6-membered saturated, partially unsaturated, or fully unsaturated ring;

i) R<sup>6</sup> is CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>OH, OH, OMe, OEt, NH<sub>2</sub>, NH(Me), NH(Et), N(Me)(Me), CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, NHCO<sub>2</sub>*t*-butyl, phenyl, cyclopentyl, methyl, ethyl, isopropyl, cyclopropyl, NH(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>, NH(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, NH(CH<sub>2</sub>)<sub>2</sub>NHET, NHCH<sub>2</sub>pyridyl, NHSO<sub>2</sub>phenyl, NHC(O)CH<sub>2</sub>C(O)O*t*-butyl, NHC(O)CH<sub>2</sub>NH<sub>3</sub>, and NHCH<sub>2</sub>-imidazol-4-yl;







j) Ar<sup>1</sup> is ring **a**, **e**, **i**, **k**, **cc**, **jj**, or **pp** wherein t is 0, 1, 2, or 3, and T is a bond or is an optionally substituted C<sub>1-6</sub> alkylidene chain wherein one or two methylene units are optionally and independently replaced by -O-, -NR-, -S-, -SO<sub>2</sub>-, -COO-, -CO-, -OSO<sub>2</sub>-, -NRSO<sub>2</sub>-, -CONR-, or -SO<sub>2</sub>NR-, and R<sup>7</sup> is R' or halogen; or

k) Ar<sup>1</sup> is ring **a**, **e**, **i**, **k**, **cc**, **jj**, or **pp** wherein t is 0, 1, 2, or 3, and each occurrence of TR<sup>7</sup> is independently -C<sub>1-3</sub>alkyl, -OR', -SR', -CF<sub>3</sub>, -OCF<sub>3</sub>, -SCF<sub>3</sub>, -F, -Cl, I, -Br, -COOR', -COR', -O(CH<sub>2</sub>)<sub>4</sub>N(R)(R'), -O(CH<sub>2</sub>)<sub>3</sub>N(R)(R'), -O(CH<sub>2</sub>)<sub>2</sub>N(R)(R'), -O(CH<sub>2</sub>)N(R)(R'), -O(CH<sub>2</sub>)<sub>4</sub>CON(R)(R'), -O(CH<sub>2</sub>)<sub>3</sub>CON(R)(R'), -O(CH<sub>2</sub>)<sub>2</sub>CON(R)(R'), -O(CH<sub>2</sub>)CON(R)(R'), -C(O)N(R)(R'), -(CH<sub>2</sub>)<sub>4</sub>OR', -(CH<sub>2</sub>)<sub>3</sub>OR', -(CH<sub>2</sub>)<sub>2</sub>OR', -CH<sub>2</sub>OR', optionally substituted phenyl or benzyl, -N(R)(R'), -(CH<sub>2</sub>)<sub>4</sub>N(R)(R'), -(CH<sub>2</sub>)<sub>3</sub>N(R)(R'),

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

$-(\text{CH}_2)_2\text{N}(\text{R})(\text{R}')$ ,  $-(\text{CH}_2)\text{N}(\text{R})(\text{R}')$ ,  $-\text{SO}_2\text{N}(\text{R})(\text{R}')$ ,  $-\text{NR}\text{SO}_2\text{R}'$ ,  $-\text{CON}(\text{R})(\text{R}')$ , or  $-\text{OSO}_2\text{R}'$ .

37. (Currently amended) The compound of claim 34 or 35, q is 1, and  $\text{Ar}^1$  is optionally substituted phenyl and compounds of general formula XIV-A through XIX-A are provided:



wherein:

each occurrence of  $\text{R}^1$  is hydrogen;

each occurrence of  $\text{R}^Z$  is hydrogen;

$\text{R}^2$  is hydrogen, or is  $\text{U}_n\text{R}'$ , where n is 1, and U is  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ,



Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

$-\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{O}-$ ,  $-\text{CH}_2\text{S}-$ ,  $-\text{CH}_2\text{NR}-$ ,  $-\text{CH}_2\text{CH}_2\text{O}-$ ,  
 $-\text{CH}_2\text{CH}_2\text{S}-$ ,  $-\text{CH}_2\text{CH}_2\text{NR}-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{S}-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{NR}-$ ,  
 $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{O}-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{S}-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{NR}-$ ,  $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$ ,  
 $-(\text{CH}_2)_4\text{NHCH}_2-$ ,  $-(\text{CH}_2)_3\text{NHCH}_2\text{CH}_2-$ , or  $-\text{CH}_2\text{CH}_2\text{NHCH}_2\text{CH}_2-$ , and  $\text{R}'$  groups are  
hydrogen,  $\text{C}_1$ - $\text{C}_4$ alkyl, optionally substituted tetrahydropyranyl, pyrrolidinyl, piperidinyl,  
piperazinyl, morpholinyl, thiomorpholinyl, pyridinyl, phenyl, or cyclohexyl, or  $\text{R}$  and  $\text{R}'$ ,  
taken together with the nitrogen atom to which they are bound, form an optionally  
substituted 5- or 6-membered heterocyclcyl ring;


each occurrence of  $\text{R}^4$  is independently hydrogen,  $\text{C}_{1-6}$ aliphatic,  $\text{CN}$ ,  $\text{COR}$ ,  
 $\text{COOR}$ ,  $\text{CON}(\text{R})_2$ , or halogen;

$\text{R}^6$  is  $\text{R}'$ ,  $-\text{N}(\text{R})(\text{R}')$ ,  $-(\text{CH}_2)_{1-4}\text{N}(\text{R})(\text{R}')$ ,  $-\text{OR}'$ ,  $-(\text{CH}_2)_{1-4}\text{OR}'$ ,  
 $-\text{NR}(\text{CH}_2)_{1-4}\text{N}(\text{R})(\text{R}')$ ,  $-\text{NR}(\text{CH}_2)_{1-4}\text{SO}_2\text{R}'$ ,  $-\text{NR}(\text{CH}_2)_{1-4}\text{COOR}'$ , or  
 $-\text{NR}(\text{CH}_2)_{1-4}\text{COR}'$ ; and


$t$  is 0, 1, 2, or 3, and each occurrence of  $\text{TR}^7$  is independently  $-\text{C}_{1-3}$ alkyl,  $-\text{OR}'$ ,  
 $-\text{SR}'$ ,  $-\text{CF}_3$ ,  $-\text{OCF}_3$ ,  $-\text{SCF}_3$ ,  $-\text{F}$ ,  $-\text{Cl}$ ,  $\text{I}$ ,  $-\text{Br}$ ,  $-\text{COOR}'$ ,  $-\text{COR}'$ ,  $-\text{O}(\text{CH}_2)_4\text{N}(\text{R})(\text{R}')$ ,  
 $-\text{O}(\text{CH}_2)_3\text{N}(\text{R})(\text{R}')$ ,  $-\text{O}(\text{CH}_2)_2\text{N}(\text{R})(\text{R}')$ ,  $-\text{O}(\text{CH}_2)\text{N}(\text{R})(\text{R}')$ ,  $-\text{O}(\text{CH}_2)_4\text{CON}(\text{R})(\text{R}')$ ,  
 $-\text{O}(\text{CH}_2)_3\text{CON}(\text{R})(\text{R}')$ ,  $-\text{O}(\text{CH}_2)_2\text{CON}(\text{R})(\text{R}')$ ,  $-\text{O}(\text{CH}_2)\text{CON}(\text{R})(\text{R}')$ ,  $-\text{C}(\text{O})\text{N}(\text{R})(\text{R}')$ ,  
 $-(\text{CH}_2)_4\text{OR}'$ ,  $-(\text{CH}_2)_3\text{OR}'$ ,  $-(\text{CH}_2)_2\text{OR}'$ ,  $-\text{CH}_2\text{OR}'$ , optionally substituted phenyl or  
benzyl,  $-\text{N}(\text{R})(\text{R}')$ ,  $-(\text{CH}_2)_4\text{N}(\text{R})(\text{R}')$ ,  $-(\text{CH}_2)_3\text{N}(\text{R})(\text{R}')$ ,  $-(\text{CH}_2)_2\text{N}(\text{R})(\text{R}')$ ,  
 $-(\text{CH}_2)\text{N}(\text{R})(\text{R}')$ ,  $-\text{SO}_2\text{N}(\text{R})(\text{R}')$ ,  $-\text{NRSO}_2\text{R}'$ ,  $-\text{CON}(\text{R})(\text{R}')$ , or  $-\text{OSO}_2\text{R}'$ .

38. (Previously presented) The compound of claim 16, wherein  $\text{R}^2$  and  $\text{Q}^1\text{-R}^3$ , taken  
together with the atoms to which they are bound form a 5-membered cyclic group, and  
compounds have the general formula **XX** through **XXV**:


Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862




XX




XXI




XXII



XXIII




XXIV




XXV.

39. (Previously presented) The compound of claim 16, R<sup>2</sup> and Q<sup>1</sup>-R<sup>3</sup>, taken together with the atoms to which they are bound form a 5-membered cyclic group, and compounds have the general formula **XXVI** through **XXXI**:




XXVI




XXVII


Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862




XXVIII



XXIX




XXX




XXXI.



40. (Previously presented) The compound of claim 16, wherein  $R^2$  and  $Q^1-R^3$ , taken together with the atoms to which they are bound form a 6-membered cyclic group, and compounds have the general formula XXXII through XXXVII:



XXXII




XXXIII




Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862

XXXIV



XXXVI

XXXV



XXXVII

wherein W is O, NR<sup>5</sup>, or CHR<sup>5</sup>.

41. (Original) The compound of claims 38, 39 or 40, wherein compound variables are selected from one of more of the following groups:

- a) each occurrence of R<sup>1</sup> is independently hydrogen, halogen, optionally substituted C<sub>1</sub>-C<sub>4</sub>aliphatic, OR, SR, or N(R)<sub>2</sub>;
- b) each occurrence of R<sup>Z</sup> is independently hydrogen, halogen, optionally substituted C<sub>1</sub>-C<sub>4</sub>aliphatic, OH, OR' or N(R)(R')
- c) each occurrence of R<sup>4</sup> is independently hydrogen, C<sub>1-6</sub>aliphatic, CN, COR, COOR, CON(R)<sub>2</sub>, or halogen;
- d) R<sup>5</sup> is hydrogen, (CH<sub>2</sub>)<sub>3</sub>OR', (CH<sub>2</sub>)<sub>2</sub>OR', (CH<sub>2</sub>)OR', (CH<sub>2</sub>)<sub>3</sub>N(R')<sub>2</sub>, (CH<sub>2</sub>)<sub>2</sub>N(R')<sub>2</sub>, (CH<sub>2</sub>)N(R')<sub>2</sub>, or C<sub>1-4</sub>aliphatic;
- e) Q<sup>3</sup> is a direct bond, or is -(CHR<sup>6</sup>)<sub>q</sub>-, -(CHR<sup>6</sup>)<sub>q</sub>O-, -(CHR<sup>6</sup>)<sub>q</sub>S-, -(CHR<sup>6</sup>)<sub>q</sub>S(O)<sub>2</sub>-, -(CHR<sup>6</sup>)<sub>q</sub>S(O)-, -(CHR<sup>6</sup>)<sub>q</sub>NR-, or -(CHR<sup>6</sup>)<sub>q</sub>C(O)-, wherein q is 0, 1, 2, or 3; and
- f) Ar<sup>2</sup> is ring **a**, **b**, **e**, **g**, **h**, **i**, **j**, **k**, **n**, **r**, **cc**, **dd**, **ff**, **jj**, **ll**, or **pp**, wherein t is 0, 1, 2, or 3, and T is a bond or is an optionally substituted C<sub>1-6</sub> alkylidene chain wherein one or two methylene units are optionally and independently replaced by -O-, -NR-, -S-, -SO<sub>2</sub>-, -COO-, -CO-, -OSO<sub>2</sub>-, -NRSO<sub>2</sub>-, -CONR-, or -SO<sub>2</sub>NR-, and R<sup>7</sup> is R' or halogen.

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

42. (Currently amended) The compound of claims 38, 39 or 40, wherein compound variables are selected from one of more of the following groups:

a) each occurrence of  $R^1$  is independently hydrogen, halogen,  $-CH_3$ ,  $-CH_2CH_3$ ,  $-OH$ ,  $-OCH_3$ ,  $-SCH_3$ ,  $-NH_2$ ,  $-N(CH_3)_2$ ,  $-N(CH_2CH_3)_2$ ,  $NH(CH_2)_2NHCH_3$ ,  $NH(cyclopropyl)$ ,  $NH(CH_2)cyclopropyl$ , or  $NH(CH_2)_2N(CH_3)_2$ ;

b) each occurrence of  $R^Z$  is independently hydrogen, halogen, Me, OH, OMc,  $NH_2$ , or  $N(Me)_2$ ;

c) each occurrence of  $R^4$  is independently hydrogen,  $C_{1-6}aliphatic$ , CN,  $\epsilon OR$ ,  $\epsilon OR$ ,  $CON(R)_2$ , or halogen;


d)  $R^5$  is hydrogen,  $(CH_2)_3OR'$ ,  $(CH_2)_2OR'$ ,  $(CH_2)OR'$ ,  $(CH_2)_3N(R')_2$ ,  $(CH_2)_2N(R')_2$ ,  $(CH_2)N(R')_2$ , or  $C_{1-4}aliphatic$ ;

e)  $Q^3$  is a direct bond, or is  $-(CHR^6)_q-$ ,  $-(CHR^6)_qO-$ ,  $-(CHR^6)_qS-$ ,  $-(CHR^6)_qS(O)_2-$ ,  $-(CHR^6)_qS(O)-$ ,  $-(CHR^6)_qNR-$ , or  $-(CHR^6)_qC(O)-$ , wherein q is 0, 1, 2, or 3; and


f)  $Ar^2$  is ring **a**, **b**, **e**, **g**, **h**, **i**, **j**, **k**, **n**, **r**, **cc**, **dd**, **ff**, **jj**, **ll**, or **pp**, wherein t is 0, 1, 2, or 3, and each occurrence of  $TR^7$  is independently  $-C_{1-3}alkyl$ ,  $-OR'$ ,  $-SR'$ ,  $-CF_3$ ,  $-OCF_3$ ,  $-SCF_3$ ,  $-F$ ,  $-Cl$ ,  $I$ ,  $-Br$ ,  $-COOR'$ ,  $-COR'$ ,  $-O(CH_2)_4N(R)(R')$ ,  $-O(CH_2)_3N(R)(R')$ ,  $-O(CH_2)_2N(R)(R')$ ,  $-O(CH_2)N(R)(R')$ ,  $-O(CH_2)_4CON(R)(R')$ ,  $-O(CH_2)_3CON(R)(R')$ ,  $-O(CH_2)_2CON(R)(R')$ ,  $-O(CH_2)CON(R)(R')$ ,  $-C(O)N(R)(R')$ ,  $-(CH_2)_4OR'$ ,  $-(CH_2)_3OR'$ ,  $-(CH_2)_2OR'$ ,  $-CH_2OR'$ , optionally substituted phenyl or benzyl,  $-N(R)(R')$ ,  $-(CH_2)_4N(R)(R')$ ,  $-(CH_2)_3N(R)(R')$ ,  $-(CH_2)_2N(R)(R')$ ,  $-(CH_2)N(R)(R')$ ,  $-SO_2N(R)(R')$ ,  $-NRSO_2R'$ ,  $-CON(R)(R')$ , or  $-OSO_2R'$ .

43. (Previously presented) The compound of claims 38, 39 or 40, wherein  $Ar^2$  is optionally substituted phenyl and compounds of general formula **XX-A**, through **XXXVII** are provided:


Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862




XX-A




XXI-A




XXII-A




XXIII-A




XXIV-A



XXV-A




XXVI-A




XXVII-A


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




XXVIII-A




XXIX-A




XXX-A




XXXI-A




XXXII-A



XXXIII-A




XXXIV-A




XXXV-A

Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862



XXXVI-A



XXXVII-A.

44. (Currently amended) The compound of claim 43, wherein compound variables are selected from:

each occurrence of  $R^1$  is hydrogen;

each occurrence of  $R^Z$  is hydrogen;

each occurrence of  $R^4$  is independently hydrogen,  $C_{1-6}$ aliphatic, CN, ~~COOR~~, ~~CON(R)~~, or halogen;

$R^5$  is hydrogen,  $(CH_2)_3OR'$ ,  $(CH_2)_2OR'$ ,  $(CH_2)OR'$ ,  $(CH_2)_3N(R')_2$ ,  $(CH_2)_2N(R')_2$ ,  $(CH_2)N(R')_2$ , or  $C_{1-4}$ aliphatic;


$Q^3$  is a direct bond, or is  $-(CHR^6)_q-$ ,  $-(CHR^6)_qO-$ ,  $-(CHR^6)_qS-$ ,  $-(CHR^6)_qS(O)_2-$ ,  $-(CHR^6)_qS(O)-$ ,  $-(CHR^6)_qNR-$ , or  $-(CHR^6)_qC(O)-$ , wherein q is 0, 1, 2, or 3; and

t is 0, 1, 2, or 3, and each occurrence of  $TR^7$  is independently  $-C_{1-3}$ alkyl,  $-OR'$ ,  $-SR'$ ,  $-CF_3$ ,  $-OCF_3$ ,  $-SCF_3$ ,  $-F$ ,  $-Cl$ ,  $I$ ,  $-Br$ ,  $-COOR'$ ,  $-COR'$ ,  $-O(CH_2)_4N(R)(R')$ ,  $-O(CH_2)_3N(R)(R')$ ,  $-O(CH_2)_2N(R)(R')$ ,  $-O(CH_2)N(R)(R')$ ,  $-O(CH_2)_4CON(R)(R')$ ,  $-O(CH_2)_3CON(R)(R')$ ,  $-O(CH_2)_2CON(R)(R')$ ,  $-O(CH_2)CON(R)(R')$ ,  $-C(O)N(R)(R')$ ,  $-(CH_2)_4OR'$ ,  $-(CH_2)_3OR'$ ,  $-(CH_2)_2OR'$ ,  $-CH_2OR'$ , optionally substituted phenyl or benzyl,  $-N(R)(R')$ ,  $-(CH_2)_4N(R)(R')$ ,  $-(CH_2)_3N(R)(R')$ ,  $-(CH_2)_2N(R)(R')$ ,  $-(CH_2)N(R)(R')$ ,  $-SO_2N(R)(R')$ ,  $-NRSO_2R'$ ,  $-CON(R)(R')$ , or  $-OSO_2R'$ .




Applicants: Jingrong Cao et al.  
Application No.: 10/696,862


45. (Currently amended) The compound of claim 1, having one of the structures:




I-A-1




I-A-2




I-A-3




I-A-4




I-A-5




I-A-6




I-A-7




I-A-8




I-A-9



I-A-10




I-A-11




I-A-12


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-A-13**




**I-A-14**




**I-A-15**




**I-A-16**




**I-A-17**




**I-A-18**




**I-A-19**




**I-A-20**




**I-A-21**



**I-A-22**




**I-A-23**




**I-A-24**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




I-A-25




I-A-26




I-A-27




I-A-28




I-A-29




I-A-30




I-A-31




I-A-32




I-A-33



I-A-34




I-A-35




I-A-36


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-A-37**




**I-A-38**




**I-A-39**




**I-A-40**




**I-A-41**




**I-A-42**




**I-A-43**




**I-B-6**




**I-B-19**




**I-B-20**




**I-B-21**



**I-B-22**




**I-B-23**




**I-B-24**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-25**




**I-B-26**




**I-B-27**




**I-B-28**




**I-B-29**




**I-B-30**




**I-B-31**




**I-B-32**




**I-B-33**



**I-B-34**




**I-B-35**




**I-B-36**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-37**




**I-B-38**




**I-B-39**




**I-B-40**




**I-B-41**




**I-B-42**




**I-B-43**




**I-B-44**




**I-B-45**




**I-B-46**




**I-B-47**




**I-B-48**



**I-B-49**




**I-B-50**




**I-B-51**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**1-B-52**




**1-B-53**




**1-B-54**




**1-B-55**




**1-B-56**




**1-B-57**




**1-B-58**




**1-B-59**




**1-B-60**




**1-B-61**




**1-B-62**




**1-B-63**



**1-B-64**




**1-B-65**




**1-B-66**


Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862




**1-B-67**




**1-B-68**




**1-B-69**




**1-B-70**




**1-B-71**




**1-B-72**




**1-B-73**




**1-B-74**




**1-B-75**




**1-B-76**




**1-B-77**




**1-B-78**



**1-B-79**




**1-B-80**




**1-B-81**




Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**1-B-82**




**1-B-83**




**1-B-84**




**1-B-85**




**1-B-86**




**1-B-88**




**1-B-89**




**1-B-90**




**1-B-91**




**1-B-92**




**1-B-93**



**1-B-94**




**1-B-95**




**1-B-96**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-97**




**I-B-99**




**I-B-100**




**I-B-102**




**I-B-103**




**I-B-104**




**I-B-105**




**I-B-106**




**I-B-107**




**I-B-108**



**I-B-109**




**I-B-110**




**I-B-111**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-112**




**I-B-113**




**I-B-114**




**I-B-115**




**I-B-116**




**I-B-117**




**I-B-119**




**I-B-120**




**I-B-121**




**I-B-122**




**I-B-123**



**I-B-124**




**I-B-125**




**I-B-126**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-127**




**I-B-128**




**I-B-129**




**I-B-130**




**I-B-146**




**I-B-148**




**I-B-149**




**I-B-150**




**I-B-151**



**I-B-152**




**I-B-153**




**I-B-154**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-157**




**I-B-158**




**I-B-159**




**I-B-160**




**I-B-161**




**I-B-162**




**I-B-163**




**I-B-164**




**I-B-165**




**I-B-171**




**I-B-175**



**I-B-176**




**I-B-179**




**I-B-180**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-181**




**I-B-182**




**I-B-185**




**I-B-186**




**I-B-187**




**I-B-190**



**I-B-192**




**I-B-193**




**I-B-194**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**1-B-197**




**1-B-198**




**1-B-199**




**1-B-200**




**1-B-201**




**1-B-202**




**1-B-203**




**1-B-204**




**1-B-205**



**1-B-206**




**1-B-207**




**1-B-208**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-209**




**I-B-210**




**I-B-211**




**I-B-212**




**I-B-213**




**I-B-214**




**I-B-215**



**I-B-216**




**I-B-217**




**I-B-218**




Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-219**




**I-B-220**




**I-B-221**




**I-B-222**




**I-B-223**




**I-B-224**




**I-B-225**



**I-B-226**




**I-B-227**




**I-B-228**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-229**




**I-B-230**




**I-B-231**




**I-B-232**




**I-B-233**




**I-B-234**




**I-B-235**




**I-B-236**



**I-B-237**




**I-B-238**




**I-B-239**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-240**




**I-B-241**




**I-B-242**




**I-B-243**




**I-B-244**




**I-B-245**




**I-B-246**




**I-B-247**




**I-B-248**



**I-B-249**




**I-B-250**




**I-B-251**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-252**




**I-B-253**




**I-B-254**




**I-B-275**




**I-B-276**




**I-B-277**




**I-B-278**




**I-B-279**




**I-B-280**



**I-B-281**




**I-B-282**




**I-B-283**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-284**




**I-B-285**




**I-B-286**




**I-B-287**




**I-B-288**




**I-B-289**




**I-B-290**




**I-B-291**



**I-B-292**




**I-B-293**




**I-B-294**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-295**




**I-B-296**




**I-B-297**




**I-B-298**




**I-B-299**




**I-B-300**




**I-B-301**




**I-B-302**




**I-B-303**




**I-B-304**



**I-B-306**




**I-B-307**




**I-B-308**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-B-309**




**I-B-312**




**I-B-313**




**I-B-314**




**I-B-315**




**I-B-321**




**I-B-322**




**I-B-323**




**I-B-324**



**I-B-325**




**I-B-326**




**I-B-327**



Application No.: 10/696,862




**I-B-328**





I-B-329

**I-B-330**


I-B-331




I-B-332

**I-B-333**


I-B-334






I-B-335



**I-B-336**




**I-B-337**


**I-B-338****I-B-339****I-B-340**




Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862




**I-B-341**




**I-B-342**




**I-B-343**




**I-B-344**




**I-B-345**




**I-B-346**




**I-C-1**




**I-C-2**




**I-C-3**




**I-C-4**




**I-C-5**



**I-C-6**




**I-C-7**




**I-C-8**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-C-9**




**I-C-10**




**I-C-11**




**I-C-12**




**I-C-13**




**I-C-14**




**I-C-15**



**I-C-16**




**I-C-17**




**I-C-18**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-C-19**




**I-C-20**




**I-C-21**




**I-C-22**




**I-C-23**




**I-C-24**




**I-C-25**




**I-C-26**



**I-C-27**




**I-C-28**




**I-C-30**


Applicants: Jingrong Cao et al.  
Application No.: 10/696,862




**I-C-31**




**I-C-32**




**I-C-34**




**I-C-36**




**I-C-37**



**I-C-38**



**I-C-39**



**or I-C-41.**


46. (Original) A composition comprising an effective amount of compound of claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

47-53. (Canceled)


54. (Currently amended) A method of treating or lessening the severity of a disease or disorder selected from glaucoma, Alzheimer's disease, an allergy, asthma, or diabetes in

Applicants: Jingrong Cao et al.  
 Application No.: 10/696,862

a patient, said method comprising administering to said patient a compound or a composition comprising a compound having the formula:



or a pharmaceutically acceptable salt thereof, wherein:



$R^1$  is halogen, CN,  $NO_2$ , or  $V_mR$ ;

$Z^1$  and  $Z^3$  are each independently  $CR^Z$ , and  $Z^2$  is  $CR^1$ ;

each occurrence of  $R^Z$  is independently halogen, CN,  $NO_2$ , or  $U_nR'$ ;

$R^2$  is  $U_nR'$ ;

$X^1$  and  $X^2$  are each independently  $CR^4$  or N;

each occurrence of  $R^4$  is independently halogen, CN,  $NO_2$ , or  $V_mR$ ;

each occurrence of U or V is independently an optionally substituted  $C_{1-6}$  alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by  $-NR-$ ,  $-S-$ ,  $-O-$ ,  $-CS-$ ,  $-CO_2-$ ,  $-OCO-$ ,  $-CO-$ ,  $-COCO-$ ,  $-CONR-$ ,  $-NRCO-$ ,  $-NRCO_2-$ ,  $-SO_2NR-$ ,  $-NRSO_2-$ ,  $-CONRNR-$ ,  $-NRCONR-$ ,  $-OCONR-$ ,  $-NRNR-$ ,  $-NRSO_2NR-$ ,  $-SO-$ , or  $-SO_2-$ ;

m and n are each independently 0 or 1;

each occurrence of R is independently hydrogen or an optionally substituted  $C_{1-6}$  aliphatic group; and each occurrence of  $R'$  is independently hydrogen or an optionally substituted  $C_{1-6}$  aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully



Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

bond or is a C<sub>1</sub>-C<sub>6</sub> alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -NR-, -S-, -O-, -CS-, -CO<sub>2</sub>-, -OCO-, -CO-, -COCO-, -CONR-, -NRCO-, -NRCO<sub>2</sub>-, -SO<sub>2</sub>NR-, -NRSO<sub>2</sub>-, -CONRNR-, -NRCONR-, -OCONR-, -NRNR-, -NRSO<sub>2</sub>NR-, -SO-, or -SO<sub>2</sub>;

Ar<sup>2</sup> is a 5-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar<sup>2</sup> is optionally substituted with 0-5 independent occurrences of TR<sup>7</sup>; wherein T is a bond or is a C<sub>1</sub>-C<sub>6</sub> alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by -NR-, -S-, -O-, -CS-, -CO<sub>2</sub>-, -OCO-,

-CO-, -COCO-, -CONR-, -NRCO-, -NRCO<sub>2</sub>-, -SO<sub>2</sub>NR-, -NRSO<sub>2</sub>-, -CONRNR-, -NRCONR-, -OCONR-, -NRNR-, -NRSO<sub>2</sub>NR-, -SO-, or -SO<sub>2</sub>; [[and]]

each occurrence of R<sup>7</sup> is independently R', halogen, NO<sub>2</sub>, or CN; and

each of the optional substituents of said aryl or heteroaryl ring is selected from  
halogen: -R°; -OR°; -SR°; phenyl optionally substituted with R°; -O(phenyl), optionally  
substituted with R°; -(CH<sub>2</sub>)<sub>1-2</sub>(phenyl), optionally substituted with R°; -CH=CH(phenyl),  
optionally substituted with R°; -NO<sub>2</sub>; -CN; -N(R°)<sub>2</sub>; -NR°C(O)R°; -NR°C(S)R°;  
-NR°C(O)N(R°)<sub>2</sub>; -NR°C(S)N(R°)<sub>2</sub>; -NR°CO<sub>2</sub>R°; -NR°NR°C(O)R°;  
-NR°NR°C(O)N(R°)<sub>2</sub>; -NR°NR°CO<sub>2</sub>R°; -C(O)C(O)R°; -C(O)CH<sub>2</sub>C(O)R°; -CO<sub>2</sub>R°;  
-C(O)R°; -C(S)R°; -C(O)N(R°)<sub>2</sub>; -C(S)N(R°)<sub>2</sub>; -OC(O)N(R°)<sub>2</sub>; -OC(O)R°; -C(O)N(OR°)  
R°; -C(NOR°)R°; -S(O)<sub>2</sub>R°; -S(O)<sub>3</sub>R°; -SO<sub>2</sub>N(R°)<sub>2</sub>; -S(O)R°; -NR°SO<sub>2</sub>N(R°)<sub>2</sub>;  
-NR°SO<sub>2</sub>R°; -N(OR°)R°; -C(=NH)N(R°)<sub>2</sub>; -P(O)<sub>2</sub>R°; -PO(R°)<sub>2</sub>; -OPO(R°)<sub>2</sub>;  
-(CH<sub>2</sub>)<sub>0-2</sub>NHC(O)R°; wherein each independent occurrence of R° is selected from  
hydrogen, an optionally substituted C<sub>1-6</sub> aliphatic, an unsubstituted 5-6 membered  
heteroaryl or heterocyclic ring, phenyl, -O(phenyl), or -CH<sub>2</sub>(phenyl), wherein optional

Applicants: Jingrong Cao et al.  
Application No.: 10/696,862

substituents on the aliphatic group of R° are selected from NH<sub>2</sub>, NH(C<sub>1-4</sub>aliphatic), N(C<sub>1-4</sub>aliphatic)<sub>2</sub>, halogen, C<sub>1-4</sub>aliphatic, OH, O(C<sub>1-4</sub>aliphatic), NO<sub>2</sub>, CN, CO<sub>2</sub>H, CO<sub>2</sub>(C<sub>1-4</sub>aliphatic), O(haloC<sub>1-4</sub> aliphatic), or haloC<sub>1-4</sub>aliphatic, or two independent occurrences of R°, on the same substituent or different substituents, taken together with the atom(s) to which each R° group is bound, form a 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and

each of the optional substituents on said alkylidene chain, aliphatic, cycloalkyl, or heterocyclyl is selected from the list of optional substituents of optional substituents for aryl and heteroaryl rings and further comprise =O, =S, =NNHR\*, =NN(R\*)<sub>2</sub>, =NNHC(O)R\*, =NNHCO<sub>2</sub>(alkyl), =NNHSO<sub>2</sub>(alkyl), or =NR\*, where each R\* is independently selected from hydrogen or a C<sub>1-6</sub> aliphatic group.

55. (Previously presented) The method of claim 54, wherein said compound or composition is used to treat or lessen the severity of an allergy or asthma.

56. (Previously presented) The method of claim 54, wherein said compound or composition is used to treat or lessen the severity of diabetes.

57. (New) The method of claim 54, wherein said compound or composition is used to treat or lessen the severity of glaucoma.